Accession Number:

AD1035632

Title:

A Synopsis of Personalized Medicine Projects Within the United States Air Force

Descriptive Note:

Conference Paper

Corporate Author:

59th Medical Wing San Antonio United States

Report Date:

2017-06-16

Pagination or Media Count:

6.0

Abstract:

The United States Air Forces Personalized Medicine PM program incorporates research in genetics, pharmacogenomics and proteomics to understand and optimize the prevention, diagnosis and treatment of disease. At the Center for Advanced Molecular Detection CAMD, several ongoing analyses evaluate individual genetic variations or patterns of variations with the potential as diagnostic, predictive, or prognostic markers,and with the long-term goal of facilitating individualized treatment regimes. A study elucidating the genetic epidemiology of Type 2 Diabetes Mellitus T2DM in the Military Health System MHS population provides evidence of single nucleotide polymorphisms SNPs associated with an enhanced risk of future Type 2 Diabetes Mellitus. Results indicate the majority of significant T2D risk-conferring SNPs were present in a younger stratified age group and have been shown to influence f3-cell function through transcription repression or transporter expression in the secretory vesicles of pancreatic beta-cells. A detailed statistical analysis is in progress and includes sub-categorization of the MHS cohort to reveal associations with defined subcategories,such as age group, gender, race, medication response, and any consequent pathologiesof T2DM. The ability to identify genetic markers in service members and target appropriate lifestyle interventions, far in advance of actual disease onset, has great potential to reduce disease burden and preserve the military readiness mission. Further evaluation of the utility of genetic variation will also be discussed based on pharmacogenomic therapeutic strategies specifically aimed at delaying diabetes progression.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE